glp-1 kidney protection receptor agonists are increasingly used to treat type 2 diabetes and #obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal. Read Diabetic kidney disease: Part 2

The Wolverine Blend combines both for comprehensive healing

This review provides a comprehensive overview of the PDE superfamily, with particular emphasis on the PDE1B and PDE10A isoforms

Some researchers have asked whether combining cagrilintide (the amylin component of CagriSema) with tirzepatide (the GIP/GLP-1 dual agonist) could produce even greater results

A 2019 meta-analysis noted mixed outcomes in autoimmune thyroid conditions, with some studies showing reduced TPO antibodies and improved TSH control, while others showed minimal clinical benefit

Cefaclor causes vagus nerve-mediated depression-like symptoms with gut dysbiosis in mice